Full Text View
Tabular View
No Study Results Posted
Related Studies
Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C
This study has been completed.
Study NCT00252642   Information provided by Virginia Commonwealth University

First Received on November 9, 2005.   Last Updated on December 14, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis C
Cirrhosis
Fibrosis
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
Hypertension
Hypertension, Portal
Liver Cirrhosis
More general conditions related to this trial
Cardiovascular Diseases
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Pathologic Processes
Picornaviridae Infections
RNA Virus Infections
Vascular Diseases
Virus Diseases
Interventions listed in this trial
Peginterferon Alpha-2a
Additional drug interventions recognized in this trial
Interferon-alpha
Peginterferon alfa-2a
More general drug interventions related to this trial
Anti-Infective Agents
Antiviral Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Virginia Commonwealth University
Hoffmann-La Roche


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services